Zealand Pharma Announces New Results on Lixisenatide (Lyxumia(R)1) for Type 2 Diabetes Presented by Sanofi (France) (SASY.PA) at the 21st World Diabetes Congress  
12/5/2011 9:49:37 AM

COPENHAGEN, Denmark, Dec. 5, 2011 (GLOBE NEWSWIRE) -- Zealand Pharma A/S (Copenhagen:ZEAL), a Danish biopharmaceutical company dedicated to the discovery and development of innovative peptide drugs, announces that new results on lixisenatide (Lyxumia(R)) will be presented by the company's partner Sanofi at the International Diabetes Federation's 21st World Diabetes Congress, 5 - 8 December 2011 in Dubai, United Arab Emirates. Lixisenatide is an investigational new GLP-1 agonist for once-daily dosing, discovered by Zealand Pharma and developed by Sanofi for the treatment of Type 2 diabetes.